New York – October 27, 2015 – Cooley advised the underwriters on Strongbridge Biopharma's $25 million initial public offering. Strongbridge Biopharma is a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The company now trades on The NASDAQ Global Select Market under the symbol "SBBP."
Stifel acted as the sole book-running manager for the offering. JMP Securities acted as lead manager, and Roth Capital Partners and Arctic Securities AS acted as co-managers.
The corporate securities team advising the underwriters included partners Div Gupta and Brent Siler and associates Alison Haggerty and Jon Arpino.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.